Kornimate/medical-research-clean huggingface dataset:
teen and young adult connections for support from multidisciplinary professionals & peers

Conditions: Short Bowel Syndrome; Malabsorption; Malnutrition

Summary: 12 month study testing mobile delivery of health information and connections to professionals and peers to improve health of teen/young adult hpn users.

this research study will test the effect of in-home/mobile hpn support delivered to teen and young adult home parenteral nutrition (hpn) patients and family members over handheld personal computers. effects on health status, qol, and fatigue will be assessed over time between groups of study subjects from the ages of 13 through 30 randomized to one of two groups. group one (intervention group) will receive mconnect, integrated evidence-based interventions (skill-building games, restorative naps \& peer support) via mobile ipad and internet delivery plus two real-time audiovisual encrypted connections with multidisciplinary professionals and peers. group two (control group) will receive healthy activity information via mobile ipad and internet delivery plus one real-time audiovisual encrypted connection with professionals and peers.

Eligibility criteria:
inclusion criteria: * total parenteral nutrition (tpn) patients/users and family members/caregivers (defined as those individuals involved in daily home hpn care) age 13 and older * tpn users (also called hpn users) ages 13 through 30 must be receiving intravenous nutrition for a non-malignant short bowel disorder * read, write, speak english and provide informed consent * be able to participate in group clinic visits exclusion criteria: * enteral nutrition dependency only * less than 13 years of age * 13 through 17 years of age without parental consent * currently enrolled in an intervention study or hpn management program * severe cognitive impairment * disability disorders (e.g. blindness which cannot be accommodated for active participation in the group clinics

Keywords: home parenteral nutrition hpn total parenteral nutrition tpn mconnect sbs short bowel disorder telehealth telemedicine
absolute bioavailability and nasopharyngeal absorption of intranasal ketamine

Conditions: Healthy

Summary: this is an open label, single-center study to determine the absolute bioavailability and nasopharyngeal absorption of pmi-150 (intranasal ketamine) 30 mg in healthy adult volunteers.

to examine the safety and assess the absolute bioavailability and nasopharyngeal absorption of pmi-150 30mg.

Eligibility criteria:
inclusion criteria: * healthy adults exclusion criteria: * under 18 years

Keywords: bioavailability
mek inhibitor pd-325901 to treat advanced non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: mek is a critical member of the mapk pathway involved in growth and survival of cancer cells. pd-325901 is a new drug designed to block this pathway and kill cancer cells. the purpose of this study is to study the effectiveness of pd-325901 in patients with non-small cell lung cancer. pd-325901 will be given by mouth as a pill twice a day, ct scans will be done and biopsies of a tumor and a blood sample will be taken before treatment to examine the how genes affect tumor response to the study medication. blood samples will be taken to measure the amount of drug in the blood.

this study was terminated prematurely on 23 march 2007 due to safety issues (ocular and neurological toxicity observed in another pd-0325901 study, a4581001) as well as lack of objective responses

Eligibility criteria:
inclusion criteria: * histologically documented non-small cell lung cancer with metastases (stage iv or recurrent disease) or locally advanced (stage iiib) with malignant pleural effusion with no expectation of further effects of prior anticancer therapy, and resolution of all acute toxic effects * adequate renal, liver, and bone marrow function, determined within 2 weeks prior to the first treatment and an ecog status of \<=1. * must have evidence of progression of disease within 6 months of most recent prior systemic anticancer therapy. exclusion criteria: * no parathyroid disorder or history of malignancy associated hypercalcemia * no ongoing radiation therapy or radio-cytotoxic therapy within prior 4 weeks; no immunotherapy, biologic therapy, hormonal, or molecular targeted therapy within prior 2 weeks * no concurrent serious infection or life-threatening illness (unrelated to tumor) * no history of a malignancy (other tha non-small cell lung cancer) except those treated with curative intent for skin cancer (other than melanoma) or in situ breast or cervical cancer or those treated with curative intent for any other cancer with no evidence of disease for 5 years. * no active seizure disorders or untreated brain metastases.
impact of reinforced education by wechat and short message service on the quality of bowel preparation

Conditions: Bowel Preparation Scale; Adenoma Detection Rate

Summary: high quality bowel preparation is essential for successful colonoscopy. this study aimed to assess the impact of reinforced education by wechat or short message service (sms) on the quality of bowel preparation. this prospective, endoscopist-blinded, randomized, controlled study was conducted. reinforced education groups received additional education via reminders by wechat or sms 2 days before colonoscopy. the primary outcome was the quality of the bowel preparation according to the boston bowel preparation scale (bbps). the secondary outcomes included polyp detection rate (pdr), adenoma detection rate (adr), tolerance, and subjective feelings of patients.


Eligibility criteria:
inclusion criteria: * aged 18-80 years * can access to wechat themselves or through close family members living in the same household exclusion criteria: * inpatients * pregnancy * breast feeding * history of colorectal surgery * patients allergic to peg-els based laxatives

Keywords: polyp detection rate adenoma detection rate boston bowel preparation scale
exercise in patients with glioblastoma

Conditions: Glioblastoma

Summary: patients with newly-diagnosed gbm will be given personalized exercise regimes during concurrent chemo-radiation and up to 3 months later. study aims are to investigate the feasibility and preliminary efficacy of the exercise program on progression free survival. secondary outcomes of interest include cognition, fatigue, and quality of life.

background: glioblastoma (gbm) is the most common malignant glioma in adults, with a very poor prognosis, limited new treatment options, and neurological sequelae, including physical and cognitive decline that adversely affect quality of life (qol). physical activity may be an intervention that attenuates the cognitive and physical decline associated with gbm. however, few studies examine physical activity in brain tumor patients, perhaps due to challenges in trial design, measuring outcomes, and complexity of care. aims of this work are to develop and implement an individualized exercise intervention for gbm patients to support functional independence, and to delay tumor progression and cognitive decline. methods: gbm patients scheduled to be treated with concurrent radiation and chemotherapy will be recruited from the neuro-oncology clinic at the princess margaret cancer centre. participants will receive an individualized, home-based exercise program that includes aerobic and resistance training, tailored to prior level of fitness, current physical status, and individual interests. they will undergo 1-hr standardized, validated assessments of physical and neurocognitive functions, mood, fatigue, and qol, prior to radiation, and then 3, 6, 12, and 18 months later. significance: identifying interventions that preserve or improve mobility and cognitive function will enhance qol and may lengthen progression-free survival in brain tumor patients. moreover, finding ways to help patients maintain self-care will lessen the strain on the health care system (e.g., fewer hospitalizations, delayed utilization of palliative care hospice).

Eligibility criteria:
inclusion criteria: * newly diagnosed glioblastoma * fluent in english * scheduled to be treated with concurrent chemoradiation (or within 2 weeks of starting treatment) exclusion criteria: * brain metastases secondary to non-central nervous system cancer * less than 18 years old * receiving treatment at a location other than the princess margaret cancer centre * deemed unfit to exercise by a study oncologist * lack of fluency in english * psychiatric or neurological disorders that could interfere with participation

Keywords: gbm glioblastoma brain cancer high-grade glioma glioma
a psychoeducational intervention for brain awareness, metacognition, self-efficacy and treatment motivation

Conditions: Substance Use Disorders; Alcohol Use Disorder

Summary: the aim of this study is to examine the effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders. it is an experimentally designed study with a randomized control group and repeated measurements (pre-test, mid-test, post-test).

the aim of this study is to examine the effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders. it is an experimentally designed study with a randomized control group and repeated measurements (pre-test, mid-test, post-test). 77 inpatients at the alcohol and drug addiction treatment and research center included between april and october 2021. in addition to standard treatment, psychoeducation and counseling provided as part of the brain awareness intervention for the experimental group of 39 patients. the control group of 38 patients will receive education about being healthy in addition to standard treatment and standard follow-up. patients' pathological metacognitive activities, self-efficacy perceptions and treatment motivation will assessed with the metacognition scale-30, self-efficacy scale and treatment motivation questionnaire using one-way and two-way repeated measures analysis.

Eligibility criteria:
inclusion criteria: 1. being between the ages of 18-65 and able to read and write 2. inpatient treatment with alcohol or substance abuse problem 3. to not have a psychiatric (severe depression, bipolar disorder or psychosis) or mental illness that would prevent participation in the study exclusion criteria: 1. failure to participate in more than one session despite agreeing to participate in the research 2. taking the decision to terminate treatment or early discharge by violating treatment rules during the treatment process 3. not participating in post-discharge follow-up or post-test application

Keywords: brain awareness psychoeducation metacognition self-efficacy treatment motivation
randomized study for patients with follicular lymphoma needing treatment

Conditions: Follicular Lymphoma

Summary: 2 parallel studies. * for young patients (18-60 years): randomization between chvp + interferon for 18 months and 4 chop followed by autotransplant after tbi * for elderly patients (\>60 years): randomization between chvp + interferon for 18 months and fludarabine 5 days every months for 6 months

2 parallel studies. * for young patients (18-60 years): randomization between chvp + interferon for 18 months and 4 chop followed by autotransplant after tbi * for elderly patients (\>60 years): randomization between chvp + interferon for 18 months and fludarabine 5 days every months for 6 months

Eligibility criteria:
inclusion criteria: * study 1 (young patients): being less than 61 years old with a follicular lymphoma and needing to be treated because of high ldh level, high beta-2 microglobulin level, poor performance status, or large tumoral mass (lymph node \>7 cm, symptomatic splenomegaly, pleura effusion, or sign of compression by the tumor mass) * study 2 (elderly patients): being older than 60 years with a follicular lymphoma and needing to be treated because of high ldh level, high beta-2 microglobulin level, poor performance status, or large tumoral mass (lymph node \>7 cm, symptomatic splenomegaly, pleura effusion, or sign of compression by the tumor mass) exclusion criteria: * contra-indication to anthracycline or interferon * transformation into large cell lymphoma * previous treatment * localized stage without criteria of large tumor mass * patients hiv+

Keywords: follicular lymphoma chvp + interferon fludarabine autotransplant
development of a non-invasive assessment of skeletal muscle loss in cancer patients

Conditions: Cachexia

Summary: the long-term objective of this research is to develop a non-invasive approach for early assessment of which patients are at high risk for future development of skeletal muscle atrophy. the investigators hypothesize that the rate constant for the terminal portion of the isotope decay curve following ingestion of a single oral dose of deuterated-3-methylhistidine (d-3mh) provides an accurate measure of this increased risk and that this rate constant can be measured non-invasively from timed spot urine samples. in addition, the investigators hypothesize that ingestion of a meat-containing meal will stimulate synthesis of skeletal muscle proteins to a greater extent than a non-meat-containing meal.


Eligibility criteria:
inclusion criteria: * male * 30-85 years * body mass index (bmi) \<30 kg/m2 exclusion criteria: * uncontrolled hypertension * glomerular filtration rate less than 60 ml/min/1.73 m2 * history of recurrent gastrointestinal bleeding * unable or unwilling to provide informed consent * ongoing anti-coagulant therapy
a study of incoxil food supplement in female patients with stress dominant urinary incontinence.

Conditions: Urinary Incontinence

Summary: the purpose of this study is compare the effectiveness of incoxil food supplement and pelvic floor muscle training with pelvic floor muscle training alone in the treatment of women with stress dominant urinary incontinence.

pelvic floor muscle training (pfmt) is the first line therapy recommended for the treatment of stress urinary incontinence. the study aims to investigate how poor pelvic floor muscle function can be strengthened by performing pelvic floor exercise and using a special dietary supplement at the same time, and if stress urinary incontinence can be improved more effectively than by performing pelvic floor exercise alone. the study aims to compare the clinical improvement in the symptoms of stress urinary incontinence in women who do pelvic floor muscle training exercise (pfmt) or who do pfmt exercise and use a dietary supplement. incoxil dietary supplement contains ingredients that are specifically designed to help strengthen muscles (creatine, l-leucine, zinc, calcium and magnesium). the randomized controlled clinical trial is proposed involving 34 women diagnosed with stress dominant urinary incontinence and randomized into two groups: 1) treatment with incoxil dietary supplement and pfmt; 2) treatment with placebo dietary supplement and pfmt. all women will perform pfmt daily and women in group 1 take incoxil every day, while women in the control group will take daily placebo dietary supplement for 6 weeks. at baseline assessment, patients shall undergo anamnesis, general gynecological exam, assessments of the pelvic floor based on the modified oxford scale, the presence of prolapse using the pelvic organ prolapse quantification (pop-q) system, pelvic muscle contraction will be measured using a pelvic perineometer and vaginal tactile imaging will be used for evaluation of vaginal and pelvic floor conditions. we also assess the general health of the vagina with vaginal health index scores. participants shall complete udi-6, pgi-s/i and iiq-7 questionnaires. after 6 weeks treatment the same assessments will be done to compare treatment and control group results.

Eligibility criteria:
inclusion criteria: * stress ui or stress-dominant mixed ui (stress percent score more than urge percent score) exclusion criteria: * pregnancy or less than 12-month postpartum * more than three vaginal deliveries or any prior operative delivery * self-reported symptoms of pelvic organ prolapse or pop-q stage \>2 * history of supervised pfmt within 12 months * current medications for ui * known zinc or copper deficiency or sensitivity * connective tissue disease
anxiety, stress and pain & myocardial infarction

Conditions: Myocardial Infarction

Summary: people often experience the acute phase of a myocardial infarction as a stressful and traumatic event that seems lifethreatening. such anxiety, pain and stress can lead to the development of posttraumatic stress disorder in the long run. previous studies suggest that there might be a relevant percentage of people developing posttraumatic stress disorder (ptsd) after a myocardial infarction. posttraumatic stress disorder is a risk factor for the development of coronary heart disease. the goal of this study is to detect the percentage of people that develop symptoms of anxiety, stress, and ptsd after an acute myocardial infarction.

people often experience the acute phase of a myocardial infarction as a stressful and traumatic event that seems lifethreatening. such anxiety, pain and stress can lead to the development of posttraumatic stress disorder in the long run. previous studies suggest that there might be a relevant percentage of people developing ptsd after a myocardial infarction. posttraumatic stress disorder is a risk factor for the development of coronary heart disease. the goal of this study is to detect the percentage of people that develop symptoms of anxiety, stress and ptsd after an acute myocardial infarction. patients will be examined during three times - in the acute myocardial infarction period (day 1-3), before dismissal (day 5-14) and after 6 months for a follow-up. during all times they will be given questionnaires asking about their levels of stress, anxiety and general well-being as well as tests checking their cognitive abilities (thus to find out if they decrease over time). moreover, blood samples checking cortisol levels as well as metanephrine levels will be taken in order to objectify the levels of stress that are stated by the patients. furthermore, clinical evaluations, laboratory runs (troponin), ecgs and echocardiographies will be done at all three points in time. the goal is to detect the biopsychosocial relations and to develop better prevention.

Eligibility criteria:
inclusion criteria: * willingness to participate in the study * men and women 19-90 * after myocardial infarctions * no psychiatric disease before myocardial infarction * no other severe disease influencing the immune system exclusion criteria: * non fulfilment of inclusion criteria * non-compliant patients (dementia, delirium) * steroid-therapy
bevacizumab in advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: primary liver cancer (hepatocellular carcinoma) is the fifth most common malignant disorder, with an increasing incidence in europe and the usa as a result of the high prevalence of hepatitis c. most patients are not suitable for potentially curative treatment. there is no standard palliative treatment for patients with advanced hepatocellular carcinoma (hcc), as no drug has been demonstrated to be efficient in this disease in terms of survival. the use of anti-vascular agents might be a promising approach in view of the highly vascular nature of this tumor. the aim of this phase ii trial is to evaluate the potential benefit of bevacizumab in terms of disease control rate, progression-free and overall survival in adult patients with advanced primary liver cancer. bevacizumab is an angiogenesis inhibitor already successfully used in patients with colorectal and renal cancers.


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven hcc or alpha-fetoprotein level \> 400 ng/ml together with hypervascular tumor and cirrhosis documented by ct scan or mri. * hcc not amenable to curative treatment (resection, transplantation, percutaneous ablation) * presence of at least one dimensionally measurable target lesion with largest diameter \>= 2 cm. * no previous chemoembolization, no previous radiotherapy * cancer of the liver italian program (clip) score \< 4 * world health organization (who) performance status of 2 or less * life expectancy \>= 3 months. * age \>= 18 years. * adequate hematologic functions (neutrophil count, at least 1500 per cubic millimeter; platelet count, at least 75,000 per cubic millimetre; hemoglobin, at least 8 g/dl) * adequate liver function (bilirubin, not more than 2 times the upper limit of normal); adequate renal function (serum creatinine, less than 150 micromol per liter) * adequate coagulation function * written informed consent exclusion criteria: * decompensated cirrhosis (child-pugh score \> 7) * clip score \> 4 * variceal bleeding during the previous 3 months * thromboembolic event during the previous 6 months * medical condition requiring full dose anticoagulation or anti-platelet drugs * abnormal cardiac function with history of ischemic heart disease in the previous 6 months, uncontrolled hypertension, unstable angina, severe cardiac arrhythmia, * no brain metastasis, no bone metastasis only * previous or current malignancies at other sites * no concomitant antitumor treatment including tamoxifen or somatostatin analogs * unstable systemic diseases or active uncontrolled infections. * patients (male and female) not using effective contraception if of reproductive potential.

Keywords: hepatocellular carcinoma, advanced, bevacizumab, phase ii, vgef, neovascularization
in vitro diagnostic device for the detection of strep a

Conditions: Streptococcal Sore Throat

Summary: the purpose of this trial is to show the accuracy and specificity of the liat analyzer and assay for detecting strep a at the point of care lab compared to culture.


Eligibility criteria:
inclusion criteria: * subjects who are 3 years of age or older * subjects exhibiting symptoms characteristic of pharyngitis, possibly streptococcus a, including: * presence of sore throat, and at least one other symptom from the list below: * redness of the posterior pharyngeal wall * pharyngeal or tonsillar exudate * tonsillar swelling * tender cervical lymphadenopathy * fever, \>38c at presentation or within the past 24 hours * subjects who are able to understand and consent to participation; for minors under the age of 18, this includes parent or legal guardian exclusion criteria: * subjects treated with antibiotics currently or within the previous 7 days.